Fate FT819 Shows Early Systemic Sclerosis Benefit

Company Fate Therapeutics, Inc. (Nasdaq: FATE) Event Type Early clinical data — presented at ISSCR 2026 Modality Off-the-shelf, iPSC-derived allogeneic CAR T-cell therapy Target CD19 Indication Systemic sclerosis (treatment-resistant); platform readthrough to hematologic malignancy Summary Fate Therapeutics reported that its off-the-shelf CD19 CAR T-cell therapy…